Advances in CAR-T cell therapy for malignant solid tumors.

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy is effective against hematological malignancies but faces challenges in solid tumors.
• Solid tumors present difficulties including lack of specific targets, uncertain T cell homing, and immunosuppressive microenvironments.

Purpose of the Study:

• To review recent advancements in CAR-T cell therapy for solid tumors.
• To explore strategies for optimizing CAR-T cell efficacy in solid tumor treatment.

Main Methods:

• Review of current clinical trials and research on CAR-T cell targets for solid tumors (e.g., GD2, CLDN18.2, B7H3, GPC3, EGFRvШ).
• Analysis of combination therapies (oncolytic viruses, TKIs, PD-L1 inhibitors) and genetic engineering approaches to enhance CAR-T cell function.

Main Results:

• Identified key targets and challenges for CAR-T cell therapy in solid tumors.
• Highlighted potential of combination therapies and gene editing for improved CAR-T cell performance.

Conclusions:

• CAR-T cell therapy holds potential for solid tumors, but requires overcoming specific hurdles.
• Future directions involve enhancing CAR-T cell activity, safety, persistence, and exploring novel combination strategies.